As a first-chair trial attorney for major brand and generic drug companies in over 80 Hatch-Waxman Act cases, Aziz Burgy brings a wealth of experience to pharmaceutical patent litigation. He also has experience litigating multiple biosimilars cases. Aziz is consistently recognized by leading publications for his legal prowess, including Chambers, IAM Patent 1000, LMG Life Sciences, and Benchmark Litigation. He has also been honored among the top 3% of ANDA litigators in Patexia intelligence reports.
Clients rely on Aziz to lead complex litigation in U.S. district courts, the Federal Circuit, the U.S. Court of Federal Claims, the Patent Trial and Appeal Board (PTAB), and the U.S. International Trade Commission (ITC) on their behalf. They value his ability to leverage his in-house experience and technical perspective to provide strategic guidance on FDA-related issues. Clients call Aziz an “excellent counselor and litigator” who has a “great strategic vision” and “sees the bigger picture” while crafting “creative arguments” on their behalf in litigation.
Aziz has also influenced patent-related legislation by advising Congress on the America Invents Act’s (AIA) impact on industries in which his clients operate, including the pharmaceutical, medical device, biotechnology, banking, Internet security robotics software, and GPS technology sectors
.
A frequent speaker on patent, copyright, trademark, and Hatch-Waxman Act issues, Aziz has guest lectured courses on patent law domestically at University of North Carolina at Chapel Hill and George Mason University, and internationally at National Tsing Hua University. He was a board member for the University of North Carolina (UNC) Department of Biology, where he served as a liaison to faculty, students, and alumni. He proudly supports nonprofit organizations serving indigent persons and children with intellectual disabilities in Northern Virginia and has successfully represented Afghans seeking asylum on a pro bono basis.
Before attending law school, Aziz worked as a research associate at MedImmune, Inc., a leading biotechnology company. During his time there, Aziz worked on the development of a humanized monoclonal antibody (palivizumab) with activity against respiratory syncytial virus and a vaccine consisting of self-assembling, virus-like particles for the prevention of human papillomavirus (HPV) infection of the genital tract and associated cervical cancer.
- Intellectual property